ONCAlert | Upfront Therapy for mRCC
EGFR+ Lung Cancer: Videos
Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung Cancers
4:58 PM, Mon February 17, 2020
.jpg "Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC")
Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC
7:20 PM, Tue January 21, 2020
Identification of EGFR Mutations Impacts Overall Prognosis in Lung Cancers
8:00 PM, Fri December 6, 2019
Understanding EGFR Resistance in Patients With MET-Amplified NSCLC
2:19 PM, Thu October 24, 2019
Osimertinib Improves Survival in EGFR+ NSCLC, Poses New Challenges for Resistance
1:00 PM, Fri September 13, 2019
.jpg "Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC")
Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC
8:33 PM, Mon August 12, 2019
.jpg "Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLC")
Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLC
5:01 PM, Fri July 12, 2019
Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC
6:30 PM, Tue June 18, 2019
